ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1944

Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
Abstract Number: 0844

Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
Abstract Number: 1652

Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Abstract Number: 1371

Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches
Abstract Number: 1651

Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis
Abstract Number: 1126

Synovial Cell Dysfunction in Obese Patients May Contribute to Poor Outcomes in Knee Osteoarthritis
Abstract Number: 0026

Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)
Abstract Number: 1127

Synovial Fluid Cytokines, Chemokines, and MMPs in Osteoarthritis Patients with Knee Pain Compared to RA Patients and Normal Knees
Abstract Number: 1008

Synovial Fluid IL-36γ in Patients with Enthesitis Related Arthritis (ERA) Correlates with Disease Activity and Leads to Production of IL-6 by Fibroblast Like Synoviocytes
Abstract Number: 1125

Synovial Perivascular Edema Is Associated with Altered Knee Loading Patterns During Gait in Patients with Medial Compartment-Dominant Knee Osteoarthritis
Abstract Number: 1232

Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Abstract Number: 0218

Synovitis Does Not Mediate the Relationship Between Body Mass Index and Progression of Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 1119

Systematic Review of Non-surgical Therapies for Hand Osteoarthritis
Abstract Number: 1552

Systemic Autoimmune Conditions and Hospital Admissions in Covid-19 Infection
Abstract Number: 0896

Systemic Lupus Erythematosus Disease Flares After SARS-CoV-2 Vaccination

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].